Exploring the long-term seroprevalence of SARS-CoV-2 antibodies in infants born to women with clinical or laboratory-confirmed COVID-19

Introduction: Infants are at a higher risk of severe illness with COVID-19 infection compared to older children. While COVID-19 vaccination is not recommended for young infants, they can acquire maternally-derived anti-SARS-CoV-2 antibodies passively through the placenta and breastmilk. We described...

Full description

Saved in:
Bibliographic Details
Main Authors: Uswa Jiwani, Khushboo Qaim Ali, Saleema Khowaja, Junaid Iqbal, Almas Aamir, Uzair Ansari, Muhammad Atif Habib, Sajid Soofi, Shabina Ariff
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:Pediatrics and Neonatology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1875957223002085
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850185928870461440
author Uswa Jiwani
Khushboo Qaim Ali
Saleema Khowaja
Junaid Iqbal
Almas Aamir
Uzair Ansari
Muhammad Atif Habib
Sajid Soofi
Shabina Ariff
author_facet Uswa Jiwani
Khushboo Qaim Ali
Saleema Khowaja
Junaid Iqbal
Almas Aamir
Uzair Ansari
Muhammad Atif Habib
Sajid Soofi
Shabina Ariff
author_sort Uswa Jiwani
collection DOAJ
description Introduction: Infants are at a higher risk of severe illness with COVID-19 infection compared to older children. While COVID-19 vaccination is not recommended for young infants, they can acquire maternally-derived anti-SARS-CoV-2 antibodies passively through the placenta and breastmilk. We described the persistence of infection-induced maternal antibodies in infant circulation at 9–12 months of age. Methodology: This was a cross-sectional study nested within the INTERCOVID multinational cohort study. For each COVID positive pregnant woman, two unmatched consecutive COVID negative pregnant women were enrolled between April and September 2020. Women with a positive PCR test, radiographic signs consistent with COVID-19, or at least 2 predefined symptoms of COVID-19 were considered as COVID positive. For this nested cross-sectional study, all COVID positive and either one of the COVID negative participants recruited from the Aga Khan University, Pakistan were approached 9–12 months after delivery, and maternal and infant sera were collected for antibody detection. Results: Altogether, 83 mothers provided consent, of whom 32 (38.6 %) were COVID positive and 51 (61.4 %) were COVID negative during pregnancy. Anti-SARS-CoV-2 antibodies were present in 13 (41 %) infants born to COVID positive and 19 (39 %) infants born to COVID negative mothers (p = 0.87). The presence of reactive antibodies in infants at follow-up was associated with maternal antibodies at follow-up (OR:9.50, 95 % CI:2.03–44.42; p = 0.004). COVID infection occurred in 3 (6 %) infants born to COVID negative mothers while no infant born to a COVID positive mother had a history of infection (p = 0.27). Conclusion: The presence of reactive anti-SARS-CoV-2 antibodies in infants at 9–12 months of age is associated with maternal seropositivity 9–12 months after delivery rather than maternal infection during pregnancy. Further studies are required to validate these findings and assess whether passive immunity in infants is protective against COVID-19 infection.
format Article
id doaj-art-3e738c80dfff4602811a7b4ca4e7de13
institution OA Journals
issn 1875-9572
language English
publishDate 2024-05-01
publisher Elsevier
record_format Article
series Pediatrics and Neonatology
spelling doaj-art-3e738c80dfff4602811a7b4ca4e7de132025-08-20T02:16:33ZengElsevierPediatrics and Neonatology1875-95722024-05-0165329329710.1016/j.pedneo.2023.05.014Exploring the long-term seroprevalence of SARS-CoV-2 antibodies in infants born to women with clinical or laboratory-confirmed COVID-19Uswa Jiwani0Khushboo Qaim Ali1Saleema Khowaja2Junaid Iqbal3Almas Aamir4Uzair Ansari5Muhammad Atif Habib6Sajid Soofi7Shabina Ariff8Center of Excellence in Women and Child Health, Aga Khan University, PakistanDepartment of Paediatrics and Child Health, Aga Khan University, PakistanDepartment of Paediatrics and Child Health, Aga Khan University, PakistanDepartment of Paediatrics and Child Health, Aga Khan University, PakistanDepartment of Paediatrics and Child Health, Aga Khan University, PakistanDepartment of Paediatrics and Child Health, Aga Khan University, PakistanDepartment of Paediatrics and Child Health, Aga Khan University, PakistanDepartment of Paediatrics and Child Health, Aga Khan University, PakistanDepartment of Paediatrics and Child Health, Aga Khan University, Pakistan; Corresponding author. Aga Khan Hospital, Stadium Road P.O Box 3500, Karachi, 74800, Pakistan.Introduction: Infants are at a higher risk of severe illness with COVID-19 infection compared to older children. While COVID-19 vaccination is not recommended for young infants, they can acquire maternally-derived anti-SARS-CoV-2 antibodies passively through the placenta and breastmilk. We described the persistence of infection-induced maternal antibodies in infant circulation at 9–12 months of age. Methodology: This was a cross-sectional study nested within the INTERCOVID multinational cohort study. For each COVID positive pregnant woman, two unmatched consecutive COVID negative pregnant women were enrolled between April and September 2020. Women with a positive PCR test, radiographic signs consistent with COVID-19, or at least 2 predefined symptoms of COVID-19 were considered as COVID positive. For this nested cross-sectional study, all COVID positive and either one of the COVID negative participants recruited from the Aga Khan University, Pakistan were approached 9–12 months after delivery, and maternal and infant sera were collected for antibody detection. Results: Altogether, 83 mothers provided consent, of whom 32 (38.6 %) were COVID positive and 51 (61.4 %) were COVID negative during pregnancy. Anti-SARS-CoV-2 antibodies were present in 13 (41 %) infants born to COVID positive and 19 (39 %) infants born to COVID negative mothers (p = 0.87). The presence of reactive antibodies in infants at follow-up was associated with maternal antibodies at follow-up (OR:9.50, 95 % CI:2.03–44.42; p = 0.004). COVID infection occurred in 3 (6 %) infants born to COVID negative mothers while no infant born to a COVID positive mother had a history of infection (p = 0.27). Conclusion: The presence of reactive anti-SARS-CoV-2 antibodies in infants at 9–12 months of age is associated with maternal seropositivity 9–12 months after delivery rather than maternal infection during pregnancy. Further studies are required to validate these findings and assess whether passive immunity in infants is protective against COVID-19 infection.http://www.sciencedirect.com/science/article/pii/S1875957223002085COVID-19InfantsSARS-CoV-2Seroprevalence
spellingShingle Uswa Jiwani
Khushboo Qaim Ali
Saleema Khowaja
Junaid Iqbal
Almas Aamir
Uzair Ansari
Muhammad Atif Habib
Sajid Soofi
Shabina Ariff
Exploring the long-term seroprevalence of SARS-CoV-2 antibodies in infants born to women with clinical or laboratory-confirmed COVID-19
Pediatrics and Neonatology
COVID-19
Infants
SARS-CoV-2
Seroprevalence
title Exploring the long-term seroprevalence of SARS-CoV-2 antibodies in infants born to women with clinical or laboratory-confirmed COVID-19
title_full Exploring the long-term seroprevalence of SARS-CoV-2 antibodies in infants born to women with clinical or laboratory-confirmed COVID-19
title_fullStr Exploring the long-term seroprevalence of SARS-CoV-2 antibodies in infants born to women with clinical or laboratory-confirmed COVID-19
title_full_unstemmed Exploring the long-term seroprevalence of SARS-CoV-2 antibodies in infants born to women with clinical or laboratory-confirmed COVID-19
title_short Exploring the long-term seroprevalence of SARS-CoV-2 antibodies in infants born to women with clinical or laboratory-confirmed COVID-19
title_sort exploring the long term seroprevalence of sars cov 2 antibodies in infants born to women with clinical or laboratory confirmed covid 19
topic COVID-19
Infants
SARS-CoV-2
Seroprevalence
url http://www.sciencedirect.com/science/article/pii/S1875957223002085
work_keys_str_mv AT uswajiwani exploringthelongtermseroprevalenceofsarscov2antibodiesininfantsborntowomenwithclinicalorlaboratoryconfirmedcovid19
AT khushbooqaimali exploringthelongtermseroprevalenceofsarscov2antibodiesininfantsborntowomenwithclinicalorlaboratoryconfirmedcovid19
AT saleemakhowaja exploringthelongtermseroprevalenceofsarscov2antibodiesininfantsborntowomenwithclinicalorlaboratoryconfirmedcovid19
AT junaidiqbal exploringthelongtermseroprevalenceofsarscov2antibodiesininfantsborntowomenwithclinicalorlaboratoryconfirmedcovid19
AT almasaamir exploringthelongtermseroprevalenceofsarscov2antibodiesininfantsborntowomenwithclinicalorlaboratoryconfirmedcovid19
AT uzairansari exploringthelongtermseroprevalenceofsarscov2antibodiesininfantsborntowomenwithclinicalorlaboratoryconfirmedcovid19
AT muhammadatifhabib exploringthelongtermseroprevalenceofsarscov2antibodiesininfantsborntowomenwithclinicalorlaboratoryconfirmedcovid19
AT sajidsoofi exploringthelongtermseroprevalenceofsarscov2antibodiesininfantsborntowomenwithclinicalorlaboratoryconfirmedcovid19
AT shabinaariff exploringthelongtermseroprevalenceofsarscov2antibodiesininfantsborntowomenwithclinicalorlaboratoryconfirmedcovid19